Last updated on April 18, 2014 at 17:24 EDT

MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020

November 17, 2011

DALLAS, November 17, 2011 /PRNewswire/ –

The report “Prostate Cancer Therapeutics Market (2010-2020) (Opportunity
Analysis, Pipeline Assessment and Global Market Forecast) [


]“, as the name suggests, analyzes and studies the major market
drivers, restraints, and opportunities in North America (U.S. & Canada),
Europe (Germany, France, U.K., Italy, and Spain) and emerging markets
(Brazil, India, China, Russia, Turkey, and South Korea).

Browse market data tables and in-depth TOC on Prostate Cancer
Therapeutics Market (2010-2020) (Opportunity Analysis, Pipeline Assessment
and Global Market Forecast).


Early buyers will receive 10% customization on reports.

The prostate is an exocrine gland found in men, located in the groin
area just below the bladder and in front of the rectum. In prostate cancer,
cells within the gland mutate into cancer cells. Further, these affected
cells start killing the other healthy gland cells, and can spread to the
other body parts. Prostate cancer is the second leading cause of new cancer
cases in men worldwide and the sixth leading cause of cancerous death in
men. Globally, about 899,000 men were diagnosed with prostate cancer in 2008
and it is estimated that this number will get doubled (1.7 million) by 2030.

Global prostate cancer therapeutics market [


] was valued at $2,713 million in 2010 and it is expected to
reach $6,457 million, by 2020. It is estimated that the market will grow at
a CAGR of 11.4% and 6.8% from 2010 to 2015 and 2015 to 2020 respectively. By
therapy, hormonal therapy is dominating the global prostate cancer drugs
market with 66% market share in 2010 and expected to account for 53% market
share in 2020. However, by 2020, immunotherapy and targeted therapy will
significantly gain market share due to advantages such as increase in the
overall survival and progression free survival with benign side effects

In 2010, Europe dominated the global prostate cancer drug market by
accounting to 43% market share; followed by Europe is North America with the
share of 42%.

The major players in the market as of 2010 include AstraZeneca PLC
(U.K.), Sanofi-Aventis (France), Ipsen (France), Tolmar Inc (U.S.), Abbott
(U.S.), Astellas Pharma Inc (Japan), Indevus Pharmaceuticals Inc (U.S.),
Dendreon Corporation (U.S.), and Ferring Pharmaceuticals (Switzerland).

Other Reports by MarketsandMarkets

        - Diagnostic Imaging Market @


        - Healthcare IT Market @


        - Diabetes Care Devices Market @


        - US Biopharmaceutical Industry @


        - Stem Cell Technologies Market @


Upcoming Market Research by MarketsandMarkets

        - Ultrasound Market @


        - Medical Equipments Market @


        - Wound Care Market @


        - Electronic Medical Records (EMR) Market @


About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company
based in the U.S. We publish strategically analyzed market research reports
and serve as a business intelligence partner to Fortune 500 companies across
the world.

MarketsandMarkets also provides multi-client reports, company profiles,
databases, and custom research services. MarketsandMarkets covers thirteen
industry verticals; including advanced materials, automotives and
transportation, banking and financial services, biotechnology, chemicals,
consumer goods, energy and power, food and beverages, industrial automation,
medical, pharmaceuticals [


], semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by
providing apt business insight with our huge market intelligence repository.
To know more about us and our reports, please visit our website


        Mr. Rohan
        7557 Rambler Road,
        Suite 727, Dallas, TX 75231
        Tel: +1-888-6006-441
        Email:  sales@marketsandmarkets.com
        MarketsandMarkets Blog @  http://www.marketsandmarketsblog.com


SOURCE MarketsandMarkets

Source: PR Newswire